Lv2
188 积分 2022-04-28 加入
MM-1179: Comparative Meta-Analysis of Anti–B-Cell Maturation Antigen Therapies in Relapsed/Refractory Multiple Myeloma: Teclistamab, Ciltacabtagene Autoleucel, and Idecabtagene Vicleucel
4个月前
已完结
The current and emerging immunotherapy paradigm in small-cell lung cancer
5个月前
已完结
The Good Cancer, the Barely Cancer, and the Incurable Cancer
5个月前
已完结
The Good Cancer, the Barely Cancer, and the Incurable Cancer
6个月前
已完结
NMOSD and MOGAD: Updates on diagnostic criteria
6个月前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
7个月前
已完结
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
7个月前
已完结
In vivo CAR T cell generation to treat cancer and autoimmune disease
7个月前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
7个月前
已完结
Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance
7个月前
已完结
皖公网安备34019202002308
